Drug profile · INN
nedosiran sodium
RIVFLOZA
nedosiran sodium (RIVFLOZA) is a l-lactate dehydrogenase a chain mrna rnai inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — nedosiran sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 3
- Programs
- 2
- Data quality
- 0.84
Quick answer
nedosiran sodium (RIVFLOZA) is a l-lactate dehydrogenase a chain mrna rnai inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
L-lactate dehydrogenase A chain mRNA RNAi inhibitor
Primary target: L-lactate dehydrogenase A chain mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
Frequently asked questions
What is nedosiran sodium?
nedosiran sodium (RIVFLOZA) is a l-lactate dehydrogenase a chain mrna rnai inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for nedosiran sodium?
RIVFLOZA is a marketed brand name for nedosiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nedosiran sodium?
nedosiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.